These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
692 related articles for article (PubMed ID: 18668422)
1. Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan. Ikeda F; Saika T; Sato Y; Suzuki M; Hasegawa M; Mikawa T; Kobayashi I; Tsuji A Med Mycol; 2009 Mar; 47(2):145-8. PubMed ID: 18668422 [TBL] [Abstract][Full Text] [Related]
2. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878 [TBL] [Abstract][Full Text] [Related]
3. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program. Pfaller MA; Messer SA; Rhomberg PR; Castanheira M Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853 [TBL] [Abstract][Full Text] [Related]
4. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039 [TBL] [Abstract][Full Text] [Related]
5. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods. Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252 [TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study. Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312 [TBL] [Abstract][Full Text] [Related]
7. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726 [TBL] [Abstract][Full Text] [Related]
8. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values. Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029 [TBL] [Abstract][Full Text] [Related]
9. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates. Pfaller MA; Messer SA; Rhomberg PR; Jones RN; Castanheira M J Antimicrob Chemother; 2016 Oct; 71(10):2868-73. PubMed ID: 27287236 [TBL] [Abstract][Full Text] [Related]
10. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ J Clin Microbiol; 2006 Oct; 44(10):3533-8. PubMed ID: 17021079 [TBL] [Abstract][Full Text] [Related]
11. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559 [TBL] [Abstract][Full Text] [Related]
12. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method. Pfaller MA; Hata K; Jones RN; Messer SA; Moet GJ; Castanheira M Diagn Microbiol Infect Dis; 2011 Oct; 71(2):167-70. PubMed ID: 21696907 [TBL] [Abstract][Full Text] [Related]
13. Antifungal susceptibility of Candida isolates at one institution. Katsuragi S; Sata M; Kobayashi Y; Miyoshi T; Yamashita Y; Neki R; Horiuchi C; Yamanaka K; Kamiya C; Iwanaga N; Tanaka H; Ikeda T; Yoshimatsu J Med Mycol J; 2014; 55(1):E1-7. PubMed ID: 24682093 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values. Pfaller MA; Chaturvedi V; Diekema DJ; Ghannoum MA; Holliday NM; Killian SB; Knapp CC; Messer SA; Miskou A; Ramani R Diagn Microbiol Infect Dis; 2012 Aug; 73(4):365-8. PubMed ID: 22726528 [TBL] [Abstract][Full Text] [Related]
15. Comparative study of disc diffusion and microdilution methods in susceptibility testing of micafungin against Candida species. Ramírez M; Serrano MC; Castro C; López E; Almeida C; Fernández A; Romero A; Martín-Mazuelos E J Antimicrob Chemother; 2006 Oct; 58(4):861-3. PubMed ID: 16916868 [TBL] [Abstract][Full Text] [Related]
16. In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012. Pfaller MA; Castanheira M; Messer SA; Jones RN Mycoses; 2015 Apr; 58(4):209-14. PubMed ID: 25727853 [TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ J Clin Microbiol; 2008 Jan; 46(1):150-6. PubMed ID: 18032613 [TBL] [Abstract][Full Text] [Related]
18. Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method. Espinel-Ingroff A; Arendrup M; Cantón E; Cordoba S; Dannaoui E; García-Rodríguez J; Gonzalez GM; Govender NP; Martin-Mazuelos E; Lackner M; Lass-Flörl C; Linares Sicilia MJ; Rodriguez-Iglesias MA; Pelaez T; Shields RK; Garcia-Effron G; Guinea J; Sanguinetti M; Turnidge J Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799206 [TBL] [Abstract][Full Text] [Related]
19. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains. Panizo MM; Reviákina V; Dolande M; Selgrad S Med Mycol; 2009 Mar; 47(2):137-43. PubMed ID: 18651308 [TBL] [Abstract][Full Text] [Related]
20. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005. Borg-von Zepelin M; Kunz L; Rüchel R; Reichard U; Weig M; Gross U J Antimicrob Chemother; 2007 Aug; 60(2):424-8. PubMed ID: 17562683 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]